ArticleCombinatorial chemistry & high throughput screening2026
Effects of Inhaled Corticosteroids/Long-Acting Beta-Agonists (ICS/LABA) on Airway Microbial Diversity and IL-8/IL-10 Cytokine Levels in Stable COPD.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic Obstructive Pulmonary Disease (COPD) is a severe respiratory system disorder. In recent years, the combined therapy of inhaled corticosteroids/long-acting beta-agonists (ICS/LABA) has become the primary treatment for stable COPD patients. This study aimed to investigate the effects of ICS/LABA treatment on the airway microbiota and inflammatory profiles in COPD patients. MATERIALS AND
methodsRespiratory samples were collected from 18 individuals, including 2 healthy controls, 4 COPD patients, and 12 COPD patients receiving ICS/LABA treatment. Microbial diversity sequencing was employed to analyze the respiratory microbiota, with both diversity and functional predictions performed. Inflammatory factor levels were assessed using enzyme-linked immunosorbent assay (ELISA).
resultsThe COPD group exhibited a dysregulated respiratory microbiota compared to the control group. Compared to the COPD group, patients in the ICS/LABA treatment group showed a trend toward decreased α-diversity of bacterial communities in the respiratory tract, while the α- diversity of fungi significantly increased. Post-treatment, the abundance of Streptococcus and Fusicolla decreased, whereas the abundance of
conclusionThe combined therapy of inhaled corticosteroids/long-acting beta-agonists (ICS/LABA) appears to regulate the gene functions of respiratory tract microbiota and IL-8/IL- 10 levels in stable COPD patients. These findings offer new insights into personalized COPD treatment and microbial interventions.
Indexed as
Identifiers
39917917What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.